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Abstract
Background: Antimicrobial use in livestock is one of the factors contributing to selection and spread of resistant
microorganisms in the environment. National veterinary antimicrobial consumption monitoring programs are
therefore in place in a number of countries in the European Union. However, due to differences in methodology,
results on veterinary antimicrobial consumption from these national monitoring programs cannot be compared
internationally. International comparison is highly needed to establish regulations on veterinary antimicrobial use
and reducing antimicrobial resistance. The aim of this study was to assess differences in the outcomes on veterinary
antimicrobial consumption by applying three different sets of nationally established animal defined daily dosages to
the same antimicrobial drug delivery dataset of Dutch pigs in 2012.
Methods: Delivery information for the complete Dutch pig sector for the year 2012 reported to the Netherlands
Veterinary Medicines Authority (SDa) was analysed with three differently and nationally established animal defined
daily dosages from the Netherlands and Denmark: the Defined Daily Dosage AnimalNL (DDDANL), the Animal Daily
DosageDK (ADDDK) and Defined Animal Daily DosageDK (DADDDK). For each applied Dutch product equivalent,
Danish products were identified based on authorization for pigs, active substance (including form), administration
route, concentration and dosage regimen.
Results: Consumption in number of ADDDK/Y was lower than in number of DDDANL/Y for sows/piglets and finisher
pigs, with proportions of 83.3 % and 98.3 %. Use in number of DADDDK/Y was even lower, 79.7 % for sows/piglets
and 88.1 % for finisher pigs compared to number of DDDANL/Y. At therapeutic group level proportions of number
of DADDDK/Y to number of DDDANL/Y were 63.6-150.4 % (sows/piglets) and 55.6-171.0 % (finisher pigs). Proportions
were > 100 % for the polymyxines (sows/piglets 150.4 % and finisher pigs 149.9 %) and the macrolides/lincosamides
(finisher pigs 171.0 %).
Conclusions: Differences between nationally established animal defined daily dosages caused by different
correction factors for long-acting products and national differences in authorized dosages, have a substantial
influence on the results of antimicrobial consumption in pigs. To enable international comparison of veterinary
antimicrobial consumption data, harmonized units of measurement, animal weights and animal (sub) categories are
needed.
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Background
Antimicrobial Veterinary Medicinal Product (AVMP)
use in livestock is one of the main factors contributing
to selection and spread of resistant microorganisms,
such as extended-spectrum beta-lactamase producing
microorganisms (ESBLs) [1]. The animals and their
environment form a reservoir for the transmission of
resistant pathogens to other animals and potentially to
humans [2–6]. To minimize selection and spread of
antimicrobial resistance both at national and inter-
national levels, the antimicrobial burden needs to be re-
duced [7] and more prudent use of antimicrobials in
human and veterinary medicine is necessary.
Some European countries have implemented a na-
tional system for monitoring antimicrobial consumption
by humans and animals and publish the results in na-
tional reports, such as NethMap [8], MARAN [9] and
the SDa report [10] in the Netherlands. Sales data are
used to monitor veterinary antimicrobial use, but some
national monitoring systems also use animal defined
daily dosages as their unit of measurement. The
European Medicines Agency reports sales data of veter-
inary antimicrobials per country through the European
Surveillance of Veterinary Antimicrobial Consumption
(ESVAC) project [11]. A working party of the ESVAC
aims to specify the reports for example by stratifying
sales of specific AVMPs to animal (sub) categories [12]
and to establish internationally harmonized animal de-
fined daily dosages, comparable to the units used in the
Netherlands and Denmark [10, 13] in order to enable
cross country comparison. In human medicine inter-
nationally harmonized Defined Daily Dosages (DDDs)
per active ingredient are established by the WHO [14].
DDDs are established for the main indication for which
the active ingredient is applied and corrects for differ-
ences in dosing between various active ingredients for
the same indication . Because DDDs are internationally
applied in reporting medicine use, the results in these
reports are suitable for direct international comparison.
Animal defined daily doses, however, are currently only
established at a national level. The principle of the ani-
mal defined daily dosage is to establish a standard dose
per product, per animal species, per day to correct for
differences in dosing between antimicrobials and animal
species. Therefore, the principle of this unit of meas-
urement for monitoring of antimicrobial consumption
is the same in the different countries where it is ap-
plied. However, due to national product availability,
legal considerations such as differences in authorized
indications and dosages (since authorization of medi-
cinal products still occurs mainly on a national rather
than on an European level) differences in animal de-
fined daily dosages applied in different countries can
be expected. This lack of uniformity complicates
international comparison of the results from national
veterinary antimicrobial drug consumption monitoring
programs.
Postma et al. [15] recently presented a concept for es-
tablishing internationally harmonized animal defined
daily dosages, based on the national authorization docu-
ments of individual AVMPs in multiple countries, and
described the benefits and limitations of this method. A
comparison and review of possible differences between
nationally established animal defined daily dosages,
however, has not yet been performed. The objective of
this study was to compare the animal defined daily
dosages applied (currently or in the past) in national
veterinary antimicrobial drug consumption monitoring
programmes of two countries, to determine whether
there are differences and, if differences exist, to analyse
the magnitude of these differences. We did this by
reviewing the consequences on the outcome on anti-
microbial consumption when different animal defined
daily dosages were applied to the same dataset of anti-
microbial drug deliveries to Dutch pig farms.
Methods
Animal defined daily dosages
The defined daily dose animal (DDDA) is the unit of
measurement for the determination of annual veterinary
antimicrobial drug consumption. In the Netherlands,
DDDA’s are derived from Dutch AVMP authorization
documents and we will refer to this parameter as the
DDDANL. The DDDANL is established per AVMP and
species and represents the amount of AVMP (in g or mL
or pieces) needed for the treatment of one kg of animal
for one day in accordance to the mean authorized dos-
age for the target animal. The DDDANL for AVMPs with
a prolonged duration of action (i.e. more than 24 h) or a
shorter duration of action (applied 2 times daily) are cor-
rected for this by a correction factor either retrieved
from the authorization documents or based on expert
consensus within the SDa. Full details on DDDANL
definition as well as data collection, exact contents of
datasets, and calculation of the total veterinary anti-
microbial consumption in livestock were published
previously [16, 17].
A comparable parameter for calculation of annual
antimicrobial drug consumption is referred to as Animal
Daily Dose (ADDDK). The ADDDK is the assumed aver-
age maintenance dose needed to treat one kg of animal
during one day for the main indication in the target spe-
cies in accordance with the Danish authorization docu-
ment of the specific AVMP [13, 18]. The ADDDK was
applied as the unit of measurement in DANMAP 2009–
2011. In the provided data for this study the ADDDK was
expressed as the amount of an AVMP (in g or mL or
pieces) needed per kg animal per day.
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The third applied animal defined daily dosages are the
Defined Animal Daily Dose (DADDDK) as reported since
DANMAP 2012 [19]. The DADDDK is specified per ani-
mal species and is a standardized dose in mg/kg per day
for the main indication of a given active ingredient and a
specified route of administration and pharmaceutical
form. For orally administered antimicrobials, a differen-
tiation is made between types of formulations, for ex-
ample premixed feed or soluble powder for drinking
water medication. For some parenterally administered
active compounds a differentiation is made between im-
mediate release preparations and those with prolonged
effect [20]. Thus, the DADDDK is a measure established
at the level of the active ingredient, route of administra-
tion and pharmaceutical form and not at the level of a
specific AVMP, which are the main differences between
the establishment of this unit of measurement and the
ADDDK and DDDANL.
Data collection
Data on deliveries of AVMPs to individual farms for the
complete Dutch pig sector from the year 2012 were
collected by the quality assurance organisations of the
Dutch pig sector, and provided to the Netherlands
Veterinary Medicines Authority (SDa) for the monitor-
ing of antimicrobial consumption in livestock. Numbers
of animals per farm specified by subcategory (production
animals or finisher pigs) and farm types (sows/piglets or
finisher pigs) were incorporated in this dataset. Farms
that used a closed system housing both sows/piglets and
finisher pigs were divided in a sows/piglet farm and a
finisher pigs farm. Individual farms were recognizable by
an unique number but the encryption key was not avail-
able to the researchers, ensuring anonymous analysis of
the data.
The SDa provided the database with the DDDANL per
AVMP originally used to process the Dutch pig data of
2012 (version May 2013). A recent list of DDDANL is
publicly available on the SDa website [21]. The Danish
ADDDK used in this study were provided by the Danish
Ministry of Food, Agriculture and Fisheries. The
DADDDK per active compound defined for pigs was re-
trieved from the DADD description annex of DANMAP
2012 [20] and entered manually into a worksheet.
Data analysis
All different AVMPs, identifiable by European Article
Number (EAN), delivered to pig farms in the
Netherlands in 2012 were derived from the dataset pro-
vided by the SDa. Using the ADDDK list from the Danish
ministry of Food, Agriculture and Fisheries, Danish
equivalent products were selected for each Dutch prod-
uct. The criteria used in the selection process are shown
in Fig. 1. For some products no Danish equivalent could
be established, as no products with certain combinations
of active compounds or with a certain administration
route are authorized in Denmark. Following assessment
of the impact of deletion of these records on the number
of DDDANL/Y, the delivery records for these products
were excluded from all analyses.
Since 2013 the SDa reports the veterinary antimicro-
bial consumption in livestock as Defined Daily Dosages
Animal per year on national level, expressed in this
study as the number of DDDANL/Y (identical to the
Dutch acronym DDDANAT, but expressed differently
here to improve readability of this paper). The total
amount of packages including package size (identifiable
by EAN) delivered per year per farm type/animal cat-
egory (sows/piglets or finisher pigs) and the mean num-
bers of animals at risk per farm type per day were
derived from the data provided by the SDa. The stan-
dardized animal weights were established by the SDa
together with representatives from the Dutch pig sec-
tor. The standardized animal weights applied in all
analyses in this study are: sows/piglets 303.8 kg (=1 sow
(220 kg) + 5.5 piglets (12.5 kg each) + 0.14 gilts (107.5 kg))
and finisher pigs 70 kg.
Using the DDDANL, the delivery records and the pack-
age size using the EAN-code, the total amount of kilo-
grams of target animal that can be treated for one day
per package of AVMP can be determined. This amount
is referred to as amount of treatable kilograms*days. The
total amount of treatable kg*days were calculated per
animal (sub) category (also referred to as farm type). By
dividing this amount with the standardized animal
weight for the animal category, the total treatable num-
ber of animals*days based on the deliveries was calcu-
lated. The number of DDDANL/Y was then calculated
per farm type by dividing the total amount of treatable
animals*days by the total of animals at risk per day per
farm type. The same process was repeated to calculate
the number of ADDDK/Y and number of DADDDK/Y.
Differences between the animal defined daily dosages
DDDANL, ADDDK and DADDDK as units of measure-
ment were analysed on a more detailed level by deter-
mining the total amounts of treatment days per
therapeutic group of AVMPs (as defined by the SDa,
based on the ATCvet classification established by the
World Health Organization). Sows/piglet farms and fin-
isher pigs farm were analysed separately.
All analyses were performed using SAS® software
version 9.2 (SAS institute Inc., Cary, NC, USA).
Results
The complete Dutch dataset with deliveries of AVMPs to
pig farms in 2012 contained 228769 deliveries to a total of
6425 pig farms 2328 of which were breeding farms with
sows/piglets and 4628 were farms with finisher pigs.
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Following the algorithm as displayed in Fig. 1, a total of
13950 deliveries in 2266 farms were excluded from the
dataset (6.1 % of total deliveries in the dataset) because
there was no Danish equivalent to match the Dutch prod-
uct. For the sows/piglet farms two farms were excluded
from the dataset (2326 farms remaining) after exclusion of
these delivery records, for finisher pigs 22 farms were
excluded (4606 farms remaining). Of the 13950 excluded
records, 12729 records (91 %) were combinations of
amoxicillin/colistin, and neomycin/procainbenzylpenicil-
lin, which are combinations of antimicrobials not autho-
rized in Denmark, and trimethoprim/sulfamethoxazole
injections (oral trimethoprim/sulfamethoxazole is avail-
able in both countries).
Fig. 1 Diagram showing the selection criteria of Danish equivalent products for the Dutch AVMPs. *If the ADDDK of a product with a different
concentration correlates better with the DDDANL then this product is selected instead of the product with a matching concentration of active
compound (s). **If more than one product is eligible the product with an ADDDK closest to the DDDANL is selected
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Antimicrobial use of Dutch pigs calculated on national
level expressed in numbers of DDDANL/Y, ADDDK/Y,
DADDDK/Y are shown in Table 1. Proportions of num-
ber of ADDDK/Y and number of DADDDK/Y to the num-
ber of DDDANL/Y were calculated (after exclusion of
non-compatible deliveries and with application of Dutch
standard animal weights). For sows/piglets the number
of ADDDK/Y was 83.3 % of the number of DDDANL/Y
and the number of DADDDK/Y was 79.7 % compared to
the number of DDDANL/Y, indicating substantially lower
values if calculated by both units used in Denmark. For
finisher pigs the proportions were 98.3 % for the number
of ADDDK/Y and 88.1 % for the number of DADDDK/Y
to the number of DDDANL/Y.
Numbers of DDDANL/Y, ADDDK/Y and DADDDK/Y
per farm type at the level of therapeutic groups were
calculated and the results are shown in Table 2. This
analysis revealed an overall tendency towards lower
numbers of DADDDK/Y compared to DDDANL/Y, using
the DADDDK compared to the DDDANL as the unit of
measurement. For sows/piglets the proportions of num-
ber of DADDDK/Y compared to number of DDDANL/Y
ranged from 63.6–150.4 % but were <100 % for most
therapeutic groups of antimicrobials. Similarly, for the
finisher pigs proportions of number of DADDDK/Y
compared to number of DDDANL/Y ranged from 55.6-
171.0 %. A proportion >100 % was found for the poly-
myxines for both farm types (150.4 % and 149.9 % for
sows/piglets and finisher pigs, respectively). The propor-
tion of number of DADDDK/Y to number of DDDANL/Y
for macrolides/lincosamides was 171.0 % for the finisher
pigs only. The proportion calculated for this therapeutic
group for sows/piglets was 90.7 %. To determine why
the macrolides/lincosamides exceeded 100 % only in fin-
isher pigs we ran a detailed analysis on product level for
this antimicrobial group. We found 71.3 % of delivery
records for sows/piglets were products containing tula-
thromycin. For finisher pigs most delivery records were
products containing tylosin (89.0 %).
Discussion
In this study we show that application of different na-
tionally established animal defined daily dosages to the
same set of antimicrobial delivery data, using the same
animal (sub) categories and standardized weight for all
analyses, results in substantial differences in the reported
overall outcomes on veterinary antimicrobial consump-
tion in pigs. Differences on the outcome were observed
at the level of therapeutic groups of AVMPs. Both in-
creases and decreases were observed in treatable kilo-
grams of animals with the application of one set of
nationally defined animal daily dosages compared to
another.
Differences in several parts of the national process of
establishing a defined animal daily dosage can be identi-
fied as responsible for the observed differences. One of
these factors is the application of a correction factor to
the DDDA of long-acting formulations. As mentioned
before, the DDDANL is corrected for prolonged duration
of action. For products administered once daily the cor-
rection in DDDANL is factor 1.0. However, the duration
of action of the long-acting AVMPs exceed this 24 h and
are therefore corrected by a factor exceeding 1.0. In the
ADDDK and DADDDK the daily dosage of the AVMP
(for ADDDK) or active ingredient (for DADDDK) was re-
duced compared to the registered dose to correct for the
duration of action. For example, for some long-acting
parenteral AVMP’s with oxytetracycline, a correction
factor of 3.5 is applied to the DDDANL (for100 mL of
product, containing 200 mg active substance/mL and a
dosage of 20 mg/kg the treatable kilograms of animal are
((200/20) * 100)) * 3.5 = 3500 treatable kilograms*days).
Table 1 Antimicrobial consumption in pigs in the Netherlands in 2012 expressed as numbers of DDDANL/Y, ADDDK/Y and
DADDDK/Y is shown for all delivery records (incl.) and after exclusion of the 13950 delivery records (excl.) that could not be
matched to a Danish equivalent
Farm type No. of farms Total no. animals Total no. of treatment daysb Meanc Proportion of reference (%)
DDDANL/Y (excl.) Sows/piglets 2326 957210
a 18381559 19.2 Reference
Finisher pigs 4606 5388248 63476046 11.8 Reference
ADDDK/Y Sows/piglets 2326 957210 15328970 16.0 83.3
Finisher pigs 4606 5388248 62321913 11.6 98.3
DADDDK/Y Sows/piglets 2326 957210 14658460 15.3 79.7
Finisher pigs 4606 5388248 56189202 10.4 88.1
DDDANL/Y (incl.) Sows/piglets 2338 957315 18796613 19.6 102.1
Finisher pigs 4628 5401503 63786742 11.8 100.0
aOnly the sows are counted. The piglets and gilts are incorporated in the standardized animal weight. See text for details
bTotal treatable kilograms*days based on the antimicrobial deliveries per farm type for the whole year 2012. The total treatable kilograms*days were then divided
by the standardized animal weight (303.8 kg for sows/piglets and 70 kg for finisher pigs) to calculate total treatment days
cThe mean was calculated by dividing the total no. of treatable animals based on antimicrobial deliveries by the total number of animals present per farm type
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The ADDDK is 0.1 mL (=20 mg/kg) parenteral oxy-
tetracycline (with the same concentration) but without
correction factors and thus one package of 100 mL of
this product provides (200/20)*100 = 1000 treatable
kilograms*days. Use of long-acting products can there-
fore theoretically have a substantial influence on the
outcome of antimicrobial consumption, especially in
sub-analysis or specific (sub) categories of animals/
farms. Unfortunately, the duration of action is not al-
ways specified by the manufacturer or deducible from
pharmacokinetic studies. Therefore the applied correc-
tion factors are mostly based on consensus by national
experts and differences are therefore inevitable.
Postma et al. [15] also describe the lack of information
as a problem when establishing DDDAs for long-
acting products and the results from this study sup-
port this view.
Secondly, there is a difference in establishing the
ADDDK, DADDDK or DDDANL for products with mul-
tiple authorized indications and dosages as briefly men-
tioned in the materials and methods section. The
ADDDK and DADDDK are established by the dosage for
the main indication (following the definition of the
DDDA by the ESVAC and the DDD by the WHO) for
which the AVMP or active compound is authorized. For
example the main indication of a valnemulin containing
product has a dosage of 3–4 mg/kg per day, so the
ADDDK is defined at 3.5 mg/kg. The DDDANL is always
established as the mean of the authorized dosages for all
authorized indications for the target animal, ranging
from 1–1.5 mg/kg to 10–12 mg/kg and therefore is
established at 6 mg/kg per day.. The reason for not es-
tablishing the DDDANL on the main indication, is that
the indication for which an AVMP is used on a farm is
Table 2 Antimicrobial consumption in pigs in the Netherlands in 2012 expressed in numbers of DDDANL/Y, ADDDK/Y and DADDDK/Y
per therapeutic group and per farm type and the proportion of DADDDK/Y to DDDANL/Y
DDDANL/Y ADDDK/Y DADDDK/Y Proportion DADDDK/Y to DDDANL/Y
b (%)
Sows/piglets farms
Amphenicols 0.060 0.030 0.060 100.0
Aminoglycosides 0.004 0.003 0.003 76.7
Cephalosporins 3rd/4th gen. 0.001 0.001 0.001 100.0
Combinations 0.290 0.236 0.185 63.6
Fluoroquinolones 0.001 0.001 0.001 87.7
Macrolides/lincosamides 1.776 1.798 1.610 90.7a
Penicillins 5.685 3.882 3.580 63.0
Pleuromutilines 0.736 0.513 0.629 85.4
Polymyxines 1.207 1.199 1.815 150.4
Tetracyclines 6.931 6.640 5.778 83.3
Trimethoprim/sulfonamidesc 2.513 1.710 1.659 66.0
Total 19.20 16.01 15.32
Finisher pigs farms
Amphenicols 0.069 0.035 0.069 100.0
Aminoglycosides - - - -
Cephalosporins 3rd/4th gen. 0.000 0.000 0.000 100.0
Combinations 0.081 0.062 0.051 62.2
Fluoroquinolones 0.000 0.000 0.000 85.6
Macrolides/lincosamides 1.254 2.216 2.144 171.0a
Penicillins 1.003 0.736 0.619 61.7
Pleuromutilines 0.099 0.073 0.077 78.0
Polymyxines 0.169 0.167 0.253 149.9
Tetracyclines 7.454 7.320 6.297 84.5
Trimethoprim/sulfonamidesc 1.651 0.958 0.918 55.6
Total 11.78 11.57 10.43
aA detailed analysis of this group of antimicrobials is performed on product level. See text for details
bThis calculation is based on the unrounded numbers of DADDDK/Y and DDDANL/Y
cTrimethoprim/sulphonamides by oral use, applied in combination
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not part of the delivery data provided to the SDa by the
animal sectors. Therefore the main indication of an
AVMP can only be guessed or assumed, but there are no
data to confirm it.
Thirdly, combination products are not always available
in all countries, a problem also encountered in this
study. Excluding these products from the analysis, as
was done in this study, is one option. However, that is
only possible when these products account for only a
small part of the total antimicrobial consumption. Hand-
ling the combination products as two (or more) separate
compounds (for example separating TMPS in two com-
pounds, trimethoprim and a sulphonamide) may also
lead to over- or underestimation of antimicrobial con-
sumption. Depending on the compound authorized
dosages differ between combination therapy with mul-
tiple antimicrobials and monotherapy with the separate
compounds.
The impact of the differences mentioned above on the
outcome were illustrated by an analysis of antimicrobial
use per therapeutic group. We showed that for sows/
piglets farms there was a reduction in number of
DADDDK/Y compared to number of DDDANL/Y for
the group of macrolides/lincosamides. The same cal-
culations however increased the number of DADDDK/Y to
the number of DDDANL/Y proportion for the finisher
pigs. This indicates deliveries of very specific (different)
AVMPs for sows/piglets compared to the finisher pigs.
Therefore we performed the analysis on EAN-code
(product level) where we found the main compound
prescribed for sows/piglets farms was injectable tula-
thromycin (71.3 % of delivery records) compared to
oral tylosin in finisher pigs (89.0 % of delivery re-
cords). The difference in proportions of number of
DADDDK/Y to number of DDDANL/Y between the
two categories of animals can be explained (in part)
by the fact that a correction factor is applied to the
DDDANL of tulathromycin due to the long duration
of action of this compound (duration of action 8 days,
daily dosage 2.5/8 = 0.3125 mg/kg). The DADDDK is
also corrected for this (daily dosage 1.0 mg/kg, regis-
tered dose 2.5 mg/kg once), but the factor applied dif-
fers from the Dutch factor. The use of tulathromycin thus
results in a higher DDDANL/Y than DADDDK/Y.
For tylosin the daily dosage is higher in the
Netherlands than in Denmark, resulting in a lower
number of DDDANL/Y compared to the number of
DADDDK/Y. This finding is also in line with the study
of Postma et al. [15] as they found an international
10- fold difference between minimum and maximum
recommended dosages for tylosin for feed/water
medication, which would almost certainly be reflected
in a national DDDA if the studied countries had
established those.
Apart from the differences between the units of meas-
urement in the national veterinary antimicrobial moni-
toring programs as reviewed in this study there are
other factors in those monitoring systems that compli-
cate international comparison of veterinary antimicrobial
use. Firstly, there are differences in the definition of ani-
mal (sub) categories and secondly the differences in
standardized weights. In the Dutch data no differenti-
ation in antimicrobial deliveries to sows or (weaned) pig-
lets can be made. Therefore, sows and piglets are
analysed as one category with a standardized combined
weight of 303.8 kg/sow. In Denmark sows do include
suckling piglets but weaned piglets are a separate cat-
egory and sows and weaned piglets have their own yel-
low card category [22]. Also, the standardized weight for
a finisher pig in VETSTAT (Danish monitoring system
for veterinary drug use at herd level [23]) is 50 kg [18]
while the SDa uses a standardized weight of 70 kg for
this category of animals. In this study the standardized
weights of 303.8 kg and 70 kg were used in all analysis
to avoid this problem, but when directly comparing re-
sults from national antimicrobial consumption reports
this fact should be considered.
Also the level on which the antimicrobial consumption
is calculated in the national monitoring has to be con-
sidered in comparisons. The differences between a na-
tional level calculation, where the mean use is weighted
according to farm size, and a per farm analysis where all
farms are of equal weight can be substantial. In the
Netherlands the number of DDDANL/Y is established
both at national level and farm level (number of
DDDAF/Y). The mean of the number of DDDAF/Y, how-
ever, is lower than the number of DDDANL/Y (− 25.5 %
for sows/piglet farms and −22.0 % for finisher pig farms
for 2012) which indicates a higher use on large farms
compared to small farms, at least within the pig sector.
The calculation level (farm versus national) should there-
fore be verified before attempting across-country compari-
sons, at least when including data from the Netherlands.
Conclusion
Our study revealed interesting differences in outcomes
on antimicrobial consumption in pigs following the use
of different animal defined daily dosages. Differences in
outcomes on the use of AVMPs in an animal species can
be attributed to the applied animal defined daily dosage
due to differences in authorized indications and dosages,
but can also be a result of differences in prescription
patterns between farm types at the level of therapeutic
groups or even specific AVMPs within those groups,
next to the differences in animal (sub) categories and
standardized animal weights.
This study underlines the urgent need for inter-
national harmonized units of measurement applicable
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in monitoring systems for antimicrobial use in live-
stock, such as generic animal defined daily dosages.
But also harmonized animal (sub) categories and stan-
dardized animal weights for all animal species included in
monitoring programs should be established, as proposed
by the ESVAC.
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